drugset / Trial / NCT06976476

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

NCT06976476

Phase 2 Recruiting 100 enrolled Memorial Sloan Kettering Cancer Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).

Timeline

Start
2025-05-08
Primary completion
2029-05-08
Completion
2029-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic Subcutaneous